ADMS News and Press, Adamas Pharmaceuticals Inc. From 08/30/21

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that management will present at the following virtual investor conferences during the mo...

Image source: The Motley Fool. Adamas Pharmaceuticals Inc (NASDAQ: ADMS) Q2 2021 Earnings Call Aug 9, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Adamas Pharmaceuticals Inc (ADMS) Q2 2021 Earnings Call Transcrip...

Adamas Pharmaceuticals, Inc. (ADMS) Q2 2021 Earnings Conference Call August 09, 2021, 04:30 PM ET Company Participants Peter Vozzo - Investor Relations Neil McFarlane - Chief Executive Officer Vijay Shreedhar - Chief Commercial Officer Chris Prentiss - Chief Financial Officer Adrian Quartel -...

Second quarter 2021 total revenues of $22.0 million, a 17% increase over second quarter 2020 GOCOVRI new paid prescriptions of 730, a 97% increase over second quarter 2020 Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering m...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report second quarter 2021 financial results on Monday, August 9, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discu...

Adamas Pharmaceuticals ([[ADMS]]) announces the issuance of two patents covering Gocovri (amantadine) extended-release capsules: U.S. Patent No. 11,065,213 issued on July 20, 2021, and U.S. Patent No. 11,077,073, projected to issue on August 3, 2021.These two patents are the first issued...

-Drug-product and method-of-use patents strengthen and diversify GOCOVRI’s long-term patent portfolio- -Issuance of ADS-4101 patent in Japan for partial onset seizures in patients with epilepsy strengthens partnering opportunity- Adamas Pharmaceuticals, Inc. (...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at ...

Adamas Pharmaceuticals reported their Q1 earnings with a slight beat on EPS and a slight miss on revenue. GOCOVRI continues to report impressive growth despite a lackluster launch. Despite the commercial progress, the ADMS share price remains suppressed. It looks as if the Street is w...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that the company will present “What’s Happening in Parkinson’s Dise...